



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Antitumor agent-151

| | |
|--------------------|---|
| Cat. No.: | HY-162462 |
| Molecular Formula: | C ₂₂ H ₂₀ FN ₅ O |
| Molecular Weight: | 389.43 |
| Target: | Apoptosis |
| Pathway: | Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|--------------------|---|
| Description | Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC ₅₀ = 0.79 μM) and antitumor activity in vitro (IC ₅₀ = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis ^[1] . |
| In Vitro | Antitumor agent-151 (7k) displays a strong activity for inhibition of other AML cell lines. The IC ₅₀ values of Molm13, U937, OCI-AML2, THP-1, HL60, KASSUMI, and K562 cell lines are 30.1 ± 2.3, 78.2 ± 3.1, 39.2 ± 0.9, 79.7 ± 0.3, 40.5 ± 0.8, 41.1 ± 1.7, and 131.8 ± 1.5 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | Antitumor agent-151 (7k, 10 mg/kg, ip, Female BALB/c nude mice bearing Mv4-11 AML cells) shows powerful antitumor efficacy ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Xinrong Xiang, et al. Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. J Med Chem. 2024 Apr 25;67(8):6769-6792.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA